CBAY), resulting from allegations that CymaBay may have issued materially misleading business information to the investing public. On June 11, 2019, CymaBay announced results from an ongoing 52-week …
EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against CymaBay Therapeutics, Inc. – CBAY
EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against CymaBay Therapeutics, Inc. – CBAY
Leave a reply